Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
2025 in Review: STAAR Calls Off Alcon Acquisition Deal after Failed Vote by Shareholders
STAAR Surgical’s termination this month of its acquisition agreement with Alcon ended a five-month saga that pivoted on how the ophthalmic industry should valuate the world’s leading phakic IOL mak...
Venture Capital in Ophthalmology Doubled in 2025 to Just Under $2 Billion
Venture capital investment in ophthalmology more than doubled from 2024 to 2025, totaling just under $2 billion in 2025 compared to $934.1 million in 2024. 2025 saw $1.1 billion in early-stage fund...
Ocular Therapeutix Takes Cue from FDA, Will Submit NDA for Axpaxli After Single Phase III Trial
Ocular Therapeutix announced Dec. 8 that it planned to submit a new drug application (NDA) to the US FDA for Axpaxli in wet age-related macular degeneration (AMD) if it sees positive one-year data ...
VivaVision Needs Single US Phase III Trial for Uveitis NDA, FDA Says
VivaVision Biotech reported Jan. 6 that minutes from its meeting with the US FDA confirm that its ongoing Phase III study in China can serve as one of the two pivotal trials required to support a U...
Select US FDA Approvals and Clearances in December 2025
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in December 2025, according to the agency’s database. Remidio received clearance for its Fundus O...
Argenx Pulls Plug on Thyroid Eye Disease Program on Recommendation of Data Monitors
Dutch drugmaker Argenx reported Dec. 15 that it would discontinue the Phase III program for subcutaneous efgartigimod in moderate to severe thyroid eye disease (TED). An independent data monitoring...
US FDA Rejects Outlook’s Lytenava for a Third Time, Citing Lack of Efficacy
Outlook Therapeutics reported Dec. 31 that the US FDA had issued a third complete response letter rejecting the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation...
Meet with Market Scope at the 2026 Glaucoma 360 Meeting
Market Scope will be presenting industry data at the 2026 Glaucoma 360 meeting, set for Jan. 29-31 in San Francisco. Contact us to set up a time to discuss your custom research needs. Reach us at 3...
PDUFA Dates for Ophthalmic Drug Candidates, January 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
US FDA Extends Action Date on Aldeyra’s Reproxalap to March 2026
Aldeyra Therapeutics reported Dec. 15 that the US FDA had extended the Prescription Drug User Fee Act (PDUFA) target action date for dry eye drop candidate reproxalap to March 16, 2026. The company...
Lenz Signs Deal with Lunatus for Marketing of Vizz in Middle East
Lenz Therapeutics announced Jan. 5 an exclusive distribution agreement for Dubai’s Lunatus to develop and commercialize the presbyopia drop Vizz in the Middle East region. Under the deal, Lenz, of ...
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
Past News Stories
2025 in Review: Corporate and Surgeon Rankings of Top 10 Stories
Market Scope asked industry participants and surgeons to select the top story for 2025. Below are their choices. STAAR Calls Off Alcon Acquisition Deal after Failed Vote by Shareholders Turmoil Rei...
2025 in Review: Turmoil Reigns at US FDA, with Leadership Shuffling and High-Level Exits
A year of upheaval at the US FDA began with what amounted to a gag order on staffers from President Donald Trump and ended with the fifth person in a year taking charge of the agency’s drug evaluat...
2025 in Review: Bausch + Lomb Bounces Back from IOL Recall, Plans Busy Launch Schedule
Bausch + Lomb turned around a global recall of its enVista intraocular lenses (IOLs) in under a month in the spring of 2025, after facing a worst-case scenario for any medical device manufacturer: ...
2025 in Review: Alcon Launches Two New Platforms, Unity and Voyager
Ophthalmic industry leader Alcon launched the Unity Vitreoretinal Cataract System (VCS) and Unity Cataract System (CS) in April 2025. The devices are designed to replace Alcon’s Constellation dual-...
2025 in Review: US Refractive Surgery Volumes Hit Record Low Amid Economic Funk
Global refractive surgeries have declined in recent years, but the US refractive surgery market has experienced a sharper drop since 2021. The US economy underwent a plethora of challenges in 2025,...
2025 in Review: Sydnexis’ Atropine Drop for Myopia Rejected in US, Approved Elsewhere
The US FDA’s decision in October 2025 to reject Sydnexis’ low-dose atropine drop for myopia touched off an abundance of discussion among eye care providers—many of whom have used compounded low-dos...
2025 in Review: EssilorLuxottica Entrenches Ophthalmic Strategy with 2025 Deals
EssilorLuxottica reported Dec. 12 that it had acquired Signifeye, a network of 15 eye centers and clinics in the Flanders region of Belgium. The transaction is expected to close by Q1-2026. No fina...
2025 in Review: Multiple Cornea Therapeutic Milestones Achieved in Late 2025
The fourth quarter of 2025 saw multiple breakthroughs in cornea transplant therapies and corneal crosslinking. In October, the US FDA approved Epioxa, an epi-on version of Glaukos’ iLink corneal cr...
2025 in Review: Next-Generation PC-IOL Designs Drive Global Market Expansion in 2025
Global demand in 2025 for presbyopia-correcting intraocular lenses (PC-IOLs) increased meaningfully, driven by improved optical performance, broader participation by leading IOL manufacturers, decl...
2025 in Review: Encelto for MacTel Nabs Many Firsts, Opens New Area of Study
US FDA approval of Encelto in March 2025 handed Neurotech a cluster of firsts. It was the first therapy approved to treat macular telangiectasia type 2 (MacTel), the first encapsulated cell therapy...
Virtual Retina Could Help Unlock New Treatments for Vision Loss
New computer modeling could help scientists better understand how the retina regenerates, opening the door to new treatments for vision loss, researchers from the UK’s University of Surrey say. The...
Clinical Trial Updates for Ophthalmic Candidates , January 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.